Last Updated : August 23, 2023
Details
Generic Name:
bimekizumab
Project Status:
Pending
Therapeutic Area:
Psoriatic arthritis
Manufacturer:
UCB Canada Inc.
Call for patient/clinician input open:
Brand Name:
Bimzelx
Project Line:
Reimbursement Review
Project Number:
SR0803-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
The treatment of adult patients with active psoriatic arthritis. Bimzelx can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
The treatment of adult patients with active psoriatic arthritis. Bimzelx can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : August 23, 2023